ArticleEuropean child & adolescent psychiatry2014
Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges.
Article in European child & adolescent psychiatry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Atypical antipsychotics for disruptive behaviour disorders in children and youths.The Cochrane database of systematic reviews · 2017Pooled it
- Efficacy of atypical antipsychotics in the treatment of fecal incontinence in children and adolescents: a randomized clinical trial.BMC pediatrics · 2024Trial
- Trial
- Lingual Dyskinesia as the Presenting Feature of Acquired Demyelinating Syndrome: A Case Report and Review of Differential Diagnoses.Journal of paediatrics and child health · 2026Article
- Suicidality and associated factors among people living with mental illness attending an outpatient clinic at a tertiary hospital in Uganda.BMC psychiatry · 2026Article
- Informant Discrepancies in Suicidality Screening Tools Among School Age Youth.Child psychiatry and human development · 2024Article
- Calculated Decisions: Columbia-Suicide Severity Rating Scale (C-SSRS)Emergency medicine practice · 2019Article
- Efficacy and Safety Profile of Risperidone Long-acting Injection in Adolescents in a Real-life Setting.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2018Article
- A multi-national comparison of antipsychotic drug use in children and adolescents, 2005-2012.Child and adolescent psychiatry and mental health · 2017Article
- Identifying the gaps between science, policies, services, and the needs of youths affected by mental disorders.European child & adolescent psychiatry · 2014Article
- The poor outcome of conduct disorders: a need for innovative, more effective therapeutic interventions.European child & adolescent psychiatry · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 18 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In children and adolescents with conduct disorder (CD), pharmacotherapy is considered when non-pharmacological interventions do not improve symptoms and functional impairment. Risperidone, a second-generation antipsychotic is increasingly prescribed off-label in this indication, but its efficacy and tolerability is poorly studied in CD, especially in young people with normal intelligence. The Paediatric European Risperidone Studies (PERS) include a series of trials to assess short-term efficacy, tolerability and maintenance effects of risperidone in children and adolescents with CD and normal intelligence as well as long-term tolerability in a 2-year pharmacovigilance. In addition to its core studies, secondary PERS analyses will examine moderators of drug effects. As PERS is a large-scale academic project involving a collaborative network of expert centres from different countries, it is expected that results will lead to strengthen the evidence base for the use of risperidone in CD and improve standards of care. Challenging issues faced by the PERS consortium are described to facilitate future developments in paediatric neuropsychopharmacology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.